B2BROKER Introduces PrimeXM XCore Support & Maintenance Services for Brokers
19.2.2025 12:56:00 CET | Business Wire | Press release
B2BROKER has announced the launch of its PrimeXM XCore support and maintenance services, expanding its suite of technology solutions for brokers and financial institutions. This new solution complements the company’s existing support offerings for trading platforms, including cTrader, MT4, and MT5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217935952/en/
B2BROKER's PrimeXM XCore Service provides complete support to manage all technical aspects, including setup and ongoing maintenance, of the PrimeXM XCore server. (Graphic: Business Wire)
PrimeXM XCore in the Trading Industry
PrimeXM’s XCore is a widely used trading and aggregation engine, serving over 250 financial institutions worldwide. It provides ultra-low latency order execution, risk management capabilities, and advanced reporting tools while supporting multi-asset trading across multiple venues.
As a key component in modern brokerage infrastructure, XCore offers brokers improved liquidity access and streamlined execution. However, maintaining and managing the system can be resource-intensive, often requiring the recruitment and training of specialised personnel. Establishing an in-house team to operate XCore typically involves significant time and financial investment.
B2BROKER’s Managed PrimeXM XCore Services
Recognising the operational challenges, B2BROKER has introduced a fully managed PrimeXM XCore service designed to reduce brokers' workloads.
The new service ensures that industry professionals handle all technical aspects of the system, from setup to ongoing maintenance. This allows brokers to focus on business development and client service.
Additionally, B2BROKER introduces a dedicated audit service for clients with an existing PrimeXM server. This service involves a thorough assessment of the setup and detailed recommendations to optimise system performance and ensure a seamless transition under the company’s maintenance.
Arthur Azizov, CEO and Founder of B2BROKER, says:
"We provide comprehensive support to manage all technical aspects of PrimeXM XCore, including setup, ongoing maintenance, and day-to-day operations. No matter the number or type of liquidity providers a broker works with, B2BROKER guarantees seamless trading operations."
Clive Diethelm, CEO and Founder of PrimeXM, comments:
"By collaborating with B2BROKER, we aim to enhance our offerings with flexible support models, ensuring clients can choose solutions that best fit their requirements."
Key Features of the Service
The service package provided by B2BROKER includes:
- Comprehensive System Configuration – Full setup of trading infrastructure, including instruments, asset classes, and user access management.
- Secure Connectivity – Secure and stable integration with liquidity providers and trading venues to ensure seamless execution.
- Customisable Trading Parameters – Adaptation of trading and routing rules to align with each broker’s operational model.
- Continuous Monitoring & Support – 24/7 system oversight to maintain stability and rapid issue resolution.
- Automated Performance Reports – Generation of daily and monthly reports offering insights into system performance and trading efficiency.
Summary
By introducing this service, B2BROKER aims to simplify technical management for brokers relying on PrimeXM XCore. The fully managed approach reduces operational complexities, minimises costs associated with in-house maintenance, and ensures uninterrupted trading operations.
For brokers seeking a reliable and efficient way to manage their PrimeXM XCore infrastructure, B2BROKER’s new service provides a structured solution backed by industry expertise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217935952/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release
Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom